Microbial Inosine Promotes Immune-Checkpoint Blockade Response in Mice.

abstract：:The PD-1 inhibitor pembrolizumab in combination with chemotherapy may be an effective therapy for patients with newly diagnosed advanced non-squamous non-small cell lung cancer. In a clinical trial, patients who received the combination had an estimated 12-month overall survival rate of 69.2%, compared with 49.4% in p...

journal_title：Cancer discovery

authors：

更新日期：2018-06-01 00:00:00

abstract：:Hallin and colleagues demonstrate the preclinical activity of the KRASG12C-specific inhibitor MRTX849 in a series of in vitro and in vivo studies with supporting pilot clinical efficacy. Variable responsiveness despite effective KRASG12C inhibition highlights both the promise and potential need for combinatorial strat...

journal_title：Cancer discovery

authors： Klempner SJ,Hata AN

更新日期：2020-01-01 00:00:00

abstract：UNLABELLED:Data from 8 breast cancer genome-sequencing projects identified 25 patients with HER2 somatic mutations in cancers lacking HER2 gene amplification. To determine the phenotype of these mutations, we functionally characterized 13 HER2 mutations using in vitro kinase assays, protein structure analysis, cell cul...

journal_title：Cancer discovery

authors： Bose R,Kavuri SM,Searleman AC,Shen W,Shen D,Koboldt DC,Monsey J,Goel N,Aronson AB,Li S,Ma CX,Ding L,Mardis ER,Ellis MJ

更新日期：2013-02-01 00:00:00

abstract：:The FDA authorized 23andMe to market the first direct-to-consumer test to check for three BRCA1/2 mutations associated with a higher risk of developing breast, ovarian, and prostate cancers. The mutations are most commonly found in about 2% of women of Ashkenazi Jewish descent. ...

journal_title：Cancer discovery

authors：

更新日期：2018-05-01 00:00:00

abstract：:Epigenetic regulators, when genomically altered, may become driver oncogenes that mediate otherwise unexplained pro-oncogenic changes lacking a clear genetic stimulus, such as activation of the WNT/β-catenin pathway in melanoma. This study identifies previously unrecognized recurrent activating mutations in the G9a hi...

journal_title：Cancer discovery

authors： Kato S,Weng QY,Insco ML,Chen KY,Muralidhar S,Pozniak J,Diaz JMS,Drier Y,Nguyen N,Lo JA,van Rooijen E,Kemeny LV,Zhan Y,Feng Y,Silkworth W,Powell CT,Liau BB,Xiong Y,Jin J,Newton-Bishop J,Zon LI,Bernstein BE,Fish

更新日期：2020-07-01 00:00:00

abstract：:BRCA1-associated breast tumors display loss of BRCA1 and frequent somatic mutations of PTEN and TP53. Here we describe the analysis of BRCA1, PTEN, and p53 at the single cell level in 55 BRCA1-associated breast tumors and computational methods to predict the relative temporal order of somatic events, on the basis of t...

journal_title：Cancer discovery

authors： Martins FC,De S,Almendro V,Gönen M,Park SY,Blum JL,Herlihy W,Ethington G,Schnitt SJ,Tung N,Garber JE,Fetten K,Michor F,Polyak K

更新日期：2012-06-01 00:00:00

abstract：:Targeting the ataxia telangiectasia and RAD3-related (ATR) enzyme represents a promising anticancer strategy for tumors with DNA damage response (DDR) defects and replication stress, including inactivation of ataxia telangiectasia mutated (ATM) signaling. We report the dose-escalation portion of the phase I first-in-h...

journal_title：Cancer discovery

authors： Yap TA,Tan DSP,Terbuch A,Caldwell R,Guo C,Goh BC,Heong V,Haris NRM,Bashir S,Drew Y,Hong DS,Meric-Bernstam F,Wilkinson G,Hreiki J,Wengner AM,Bladt F,Schlicker A,Ludwig M,Zhou Y,Liu L,Bordia S,Plummer R,Lagkadin

更新日期：2020-09-28 00:00:00

abstract：:In the plasmaMATCH trial, researchers performed circulating tumor DNA testing on patients with advanced breast cancer and matched those with ESR1, HER2, or AKT1 alterations to targeted therapies. Patients with HER2 and AKT1 mutations experienced response rates greater than 22% with durable benefit. ...

journal_title：Cancer discovery

authors：

更新日期：2020-05-01 00:00:00

abstract：:Drug-induced apoptosis occurs after cells reach a p53 threshold level, which increases over time. ...

journal_title：Cancer discovery

authors：

更新日期：2016-06-01 00:00:00

abstract：:A report from the Presidential Commission for the Study of Bioethical Issues offers several recommendations to help protect the privacy of patients who have whole-genome sequencing. ...

journal_title：Cancer discovery

authors：

更新日期：2012-12-01 00:00:00

abstract：:Oncogenes induce premature S phase, resulting in replication-transcription conflicts and replication stress. ...

journal_title：Cancer discovery

authors：

更新日期：2018-04-01 00:00:00

abstract：:The combination of the antibody-drug conjugate ado-trastuzumab emtansine, or T-DM1, plus pertuzumab given prior to surgery outperformed standard therapy in women with HER2-positive breast cancer enrolled in the I-SPY 2 trial. The results, reported at the American Association for Cancer Research Annual Meeting 2016, su...

journal_title：Cancer discovery

authors：

更新日期：2016-06-01 00:00:00

abstract：:Researchers have presented a new model that uses six readily available clinical factors to predict whether a patient with advanced bladder cancer who has already received platinum chemotherapy will respond to treatment with the PD-L1 inhibitor atezolizumab. The results may help patients and their doctors decide how to...

journal_title：Cancer discovery

authors：

更新日期：2018-04-01 00:00:00

abstract：:Residual acute myeloid leukemia (AML) cells required bone marrow stromal cell-derived aspartate. ...

journal_title：Cancer discovery

authors：

更新日期：2020-10-01 00:00:00

abstract：:Global remodeling of the chromatin landscape occurs during senescence, although its functional consequence is still unclear. In this issue, Tasdemir and colleagues show that the epigenetic regulator BRD4 is required for expression of the proinflammatory senescence-associated secretory phenotype and immune clearance of...

journal_title：Cancer discovery

authors： Vizioli MG,Adams PD

更新日期：2016-06-01 00:00:00

abstract：:The FDA granted accelerated approval to selinexor plus low-dose dexamethasone for triple-class refractory multiple myeloma, despite an advisory panel's concerns about the drug's toxicity and the lack of randomized clinical data. ...

journal_title：Cancer discovery

authors：

更新日期：2019-09-01 00:00:00

abstract：:Metabolic reprogramming enables cancer cell growth, proliferation, and survival. This reprogramming is driven by the combined actions of oncogenic alterations in cancer cells and host cell factors acting on cancer cells in the tumor microenvironment. Cancer cell intrinsic mechanisms activate signal transduction compon...

journal_title：Cancer discovery

authors： Dey P,Kimmelman AC,DePinho RA

更新日期：2021-01-27 00:00:00

abstract：:Researchers have identified a new compound, OTS964, that blocks cytokinesis. Injections of the compound eliminated human lung tumors that had been transplanted into mice. Clinical trials of OTS964 may start next year. ...

journal_title：Cancer discovery

authors：

更新日期：2015-01-01 00:00:00

abstract：:An increasing number of anticancer therapeutic agents target specific mutant proteins that are expressed by many different tumor types. Recent evidence suggests that the selection of patients whose tumors harbor specific genetic alterations identifies the subset of patients who are most likely to benefit from the use ...

journal_title：Cancer discovery

authors： MacConaill LE,Van Hummelen P,Meyerson M,Hahn WC

更新日期：2011-09-01 00:00:00

abstract：UNLABELLED:Indoleamine 2,3-dioxygenase (IDO) enzyme inhibitors have entered clinical trials for cancer treatment based on preclinical studies, indicating that they can defeat immune escape and broadly enhance other therapeutic modalities. However, clear genetic evidence of the impact of IDO on tumorigenesis in physiolo...

journal_title：Cancer discovery

authors： Smith C,Chang MY,Parker KH,Beury DW,DuHadaway JB,Flick HE,Boulden J,Sutanto-Ward E,Soler AP,Laury-Kleintop LD,Mandik-Nayak L,Metz R,Ostrand-Rosenberg S,Prendergast GC,Muller AJ

更新日期：2012-08-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDA) has a poor prognosis, and new strategies for prevention and treatment are urgently needed. We previously reported that histone H4 acetylation is elevated in pancreatic acinar cells harboring Kras mutations prior to the appearance of premalignant lesions. Because acetyl-CoA abunda...

journal_title：Cancer discovery

authors： Carrer A,Trefely S,Zhao S,Campbell SL,Norgard RJ,Schultz KC,Sidoli S,Parris JLD,Affronti HC,Sivanand S,Egolf S,Sela Y,Trizzino M,Gardini A,Garcia BA,Snyder NW,Stanger BZ,Wellen KE

更新日期：2019-03-01 00:00:00

abstract：:CD14+CD16-HLA-DRhi monocyte frequency was linked to response to anti-PD-1 in patients with melanoma. ...

journal_title：Cancer discovery

authors：

更新日期：2018-03-01 00:00:00

abstract：:A new study of all 32 cancer types in The Cancer Genome Atlas identifies genomic alterations that increase the activity of the PI3K/AKT/mTOR pathway. The study, which combines mutation data with measures of protein levels and phosphorylation status, suggests that mutations in IDH1, VHL, and STK11 promote activation of...

journal_title：Cancer discovery

authors：

更新日期：2017-08-01 00:00:00

abstract：:YY1 preferentially occupies active enhancers and promoters and forms dimers to promote DNA looping. ...

journal_title：Cancer discovery

authors：

更新日期：2018-02-01 00:00:00

abstract：UNLABELLED:Colorectal cancer was one of the first solid tumors to be classified on the basis of molecular profiling. Microsatellite instability has allowed researchers to distinguish a specific subtype of colorectal cancer that has a clearly identified molecular origin (mismatch repair deficiency), arises on a heredita...

journal_title：Cancer discovery

authors： Vilar E,Tabernero J

更新日期：2013-05-01 00:00:00

abstract：:Preconditioning the immune system with a tetanus/diphtheria toxoid significantly improved the effectiveness of dendritic cell immunotherapy and extended overall survival in a small, randomized study of patients with glioblastoma. ...

journal_title：Cancer discovery

authors：

更新日期：2015-06-01 00:00:00

abstract：:The California Institute of Quantitative Biosciences offers incubators and other programs that aim to close the gap between discovery and commercialization in biotechnology. ...

journal_title：Cancer discovery

authors：

更新日期：2012-12-01 00:00:00

abstract：UNLABELLED:Although it is known that mTOR complex 2 (mTORC2) functions upstream of Akt, the role of this protein kinase complex in cancer is not well understood. Through an integrated analysis of cell lines, in vivo models, and clinical samples, we demonstrate that mTORC2 is frequently activated in glioblastoma (GBM), ...

journal_title：Cancer discovery

authors： Tanaka K,Babic I,Nathanson D,Akhavan D,Guo D,Gini B,Dang J,Zhu S,Yang H,De Jesus J,Amzajerdi AN,Zhang Y,Dibble CC,Dan H,Rinkenbaugh A,Yong WH,Vinters HV,Gera JF,Cavenee WK,Cloughesy TF,Manning BD,Baldwin AS,Mi

更新日期：2011-11-01 00:00:00

abstract：:Identifying the cancer cells-of-origin is of great interest, as it holds the potential to elucidate biologic mechanisms inherent in the normal cell state that have been co-opted to drive the oncogenic cell state. An emerging concept, proposed here, states that cancer stem cells, key players in cancer initiation and me...

journal_title：Cancer discovery

authors： Chaffer CL,Weinberg RA

更新日期：2015-01-01 00:00:00

abstract：:Although BRAF-MEK inhibition can enhance the immune recognition of melanoma cells, the mechanisms that underlie this remain poorly defined. In this issue of Cancer Discovery, Erkes and colleagues present new data showing that BRAF-MEK inhibition activates pyroptosis in melanoma cells through gasdermin E cleavage, lead...

journal_title：Cancer discovery

authors： Smalley KSM

更新日期：2020-02-01 00:00:00